English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A 59-year-old febrile woman who had been treated with methotrexate (MTX) for rheumatoid arthritis (RA) presented with a small liver nodule measuring 2 cm in diameter, which showed ring-like enhancement on contrast-enhanced abdominal computed tomography (CT). Laboratory data were within normal limits except for C-reactive protein (7.59 mg/dl, the reference range is no more than 0.20 mg/dl). Serological tests for hepatitis B virus and hepatitis C virus were negative. Soluble IL-2 receptor (561 U/ml, the reference range is 122–496 U/ml) was mildly elevated. Follow-up magnetic resonance imaging (MRI) obtained 2 months later revealed multiple larger liver nodules, showing slight T1 and T2 prolongation and restricted diffusion. On the dynamic phase of Gd-EOB-DTPA (Primovist, Bayer HealthCare, Osaka) enhancement, the lesions showed persistent ring-like enhancement from the arterial phase to the late phase. On the hepatobiliary phase image, the lesions showed diminished uptake of Gd-EOB-DTPA. 18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed multiple liver nodules with homogeneous FDG uptake, and no other foci of abnormal uptake. Percutaneous biopsy was attempted for the S6 lesion. Immunohistochemical analysis showed positive immunoreactivity for CD20, but negative for CD3 and CD5, the pathological diagnosis of diffuse large B-cell lymphoma (DLBCL) was obtained. The EBER (EBV encoded small RNA) was not tested. Considering the whole clinical information and history, MTX-associated lymphoma was considered as the final clinical diagnosis. Simple discontinuation of MTX was chosen as a treatment, then 6 months later, all of the multiple liver nodules regressed and diminishment of the ring-like enhancement was confirmed on MRI (Fig. 1A, B). C-reactive protein also showed decrease in value at this time. RA patients have higher risk of developing lymphoma. MTX is an antimetabolite administered to patients with autoimmune diseases, especially RA. Recently, it was shown that RA patients treated with MTX can develop lymphoproliferative disorders (LPDs) (MTX-LPDs) that share characteristics with the lymphomas. The incidence of MTX-LPDs among patients who are treated with MTX is about 18%.1 According to the previous reports, when compared to LPDs patients without MTX treatment (non-MTX-LPDs), the interval between the diagnosis of RA and MTX-LPDs has been reported to be significantly shorter (median 132 months) than that in non-MTX-LPDs (240 months), whereas other clinicopathological features are similar between MTX-LPDs and non-MTX-LPDs.2 MTX-LPDs tended to involve the extranodal organs such as gastrointestinal tracts, lung, and skin. On the other hand, exclusive liver involvement is extremely rare to our knowledge.3,4 MTX-LPDs of the liver have been reported to show poor enhancement or ring-like enhancement on contrast-enhanced CT, whereas there were few reports describing MRI findings. Our patient’s findings of CT and MRI were consistent with the reported classical features of primary hepatic lymphoma, but they can also be observed in other disease entities including Magn Reson Med Sci, Vol. XX, No. X, pp. XXX–XXX, 2015 ©2015 Japanese Society for Magnetic Resonance in Medicine

MR Imaging of a Methotrexate-associated Diffuse Large B-cell Lymphoma in the Liver that Regressed without Treatment